C12N15/866

RUBELLA VIRUS SPIKE CONSTRUCT

The Rubella Virus Spike construct comprises at least one E1 component and one E2 component, which are linked together. The E1 component consists of the E1 envelope protein, whose C-terminal transmembrane region and intravirional domain are removed and whose N-terminus comprises the ectodomain of the E1 envelope protein. The E2 component consists of the E2 envelope protein whose transmembrane regions and intravirional domain removed and whose C-terminus comprising the ectodomain of the E2 envelope protein. The C-terminus of the E2 component is connected to the N-terminus of the E1 component by direct fusion or by means of a linker to form an E1-E2 fusion protein.

Compositions and methods for fabricating synthetic dragline spider silk

Compositions comprising a mixture of proteins derived from MaSP, nucleic acids encoding same and method for the preparation of synthetic dragline spider silk are provided. The compositions of the invention comprise a mixture of proteins of differing molecular weight, wherein each protein of said mixture comprises, independently, multiple repeats of a repetitive region of a MaSP (major ampullate spidroin) protein or a functional homolog, variant, derivative or fragment thereof.

Compositions and methods for fabricating synthetic dragline spider silk

Compositions comprising a mixture of proteins derived from MaSP, nucleic acids encoding same and method for the preparation of synthetic dragline spider silk are provided. The compositions of the invention comprise a mixture of proteins of differing molecular weight, wherein each protein of said mixture comprises, independently, multiple repeats of a repetitive region of a MaSP (major ampullate spidroin) protein or a functional homolog, variant, derivative or fragment thereof.

A VACCINE TO PROTECT A PIG AGAINST ACTINOBACILLUS PLEUROPNEUMONIAE

The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae, the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

BACULOVIRUS EXPRESSION SYSTEM
20200407696 · 2020-12-31 · ·

The present disclosure relates to a heterologous recombinant baculovirus (rBV) expression system for the production of foreign heterologous proteins in insect cells. This system comprises a recombinant baculovirus backbone within a genome with a deletion in the cathepsin gene into which foreign gene cassettes can be integrated, and an insect cell that can be infected by the v-cath-rBV, and in which the foreign proteins and/or viral vectors or particles are expressed.

COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT
20200347102 · 2020-11-05 ·

The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT
20200347102 · 2020-11-05 ·

The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

EPIZOOTIC HEMORRHAGIC DISEASE VACCINE

The present disclosure provides for an immunogenic composition against epizootic hemorrhagic disease virus (EHDV). The immunogenic composition has been shown to be efficacious in inducing serum neutralizing antibodies against EHDV and intended to be used to prevent or reduce clinical symptoms associated with EHDV infection in susceptible animals. The disclosure provides for composition and methods that represent an improvement over previous strategies for treating and preventing EHDV.

TRANSGENIC SILKWORM HAVING MAMMALIAN-TYPE SUGAR CHAIN ATTACHED THERETO

It is intended to develop and provide a technique of conveniently allowing a transgenic silkworm by itself and at an individual level to produce a recombinant protein having a mammalian-type sugar chain sialic acid attached thereto, without the need of a baculovirus expression system or oral and transdermal administration of sialic acid. An expression vector was developed which can induce the expression of a mammalian-type glycosylation-related gene group only in a silk gland such that the recombinant protein modified with the mammalian-type sugar chain has no adverse effect on the silkworm itself. A transgenic silkworm harboring the expression vector was prepared.

TRANSGENIC SILKWORM HAVING MAMMALIAN-TYPE SUGAR CHAIN ATTACHED THERETO

It is intended to develop and provide a technique of conveniently allowing a transgenic silkworm by itself and at an individual level to produce a recombinant protein having a mammalian-type sugar chain sialic acid attached thereto, without the need of a baculovirus expression system or oral and transdermal administration of sialic acid. An expression vector was developed which can induce the expression of a mammalian-type glycosylation-related gene group only in a silk gland such that the recombinant protein modified with the mammalian-type sugar chain has no adverse effect on the silkworm itself. A transgenic silkworm harboring the expression vector was prepared.